References
- . Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103(2):137–149
- . Beagley J, Guariguata L, Weil C, Motala AA. Global estimates of undiagnosed diabetes in adults. Diabetes Res Clin Pract. 2014;103(2):150–160
- . Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442
- . Unwin N, Setel P, Rashid S,. Noncommunicable diseases in sub-Saharan Africa: where do they feature in the health research agenda? Bull World Health Organ. 2001;79(10):947–953
- . Aje TO, Miller M. Cardiovascular disease: a global problem extending into the developing world. World J Cardiol. 2009;1(1):3–10
- . Ringborg A, Cropet C, Jönsson B, Gagliardino JJ, Ramachandran A, Lindgren P. Resource use associated with type 2 diabetes in Asia, Latin America, the Middle East and Africa: results from the International Diabetes Management Practices Study (IDMPS). Int J Clin Pract. 2009;63(7):997–1007
- . US Department of Health and Human Services. US Food and Drug Administration (FDA). What are Generic Drugs? http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingGenericDrugs/ucm144456.htm. Accessed July 7, 2014
- . US Department of Health and Human Services. US Food and Drug Administration (FDA). Information for Consumers (Biosimilars). http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsare-DevelopedandApproved/ApprovalApplications/TherapeuticBiologic-Applications/Biosimilars/ucm241718.htm. Accessed July 7, 2014
- . Sandoz. Zarzio® overtakes Neupogen® and Granocyte® to become most prescribed daily G-CSF in Europe. July, 2013. http://www.sandoz.com/media_center/press_releases_news/global_news/zarzio_reg_overtakes_neupogen_reg_and_granocyte_reg_to_become_most_prescribed_daily_g-csf_in_europe_.shtml. Accessed July 7, 2014
- . Haustein R, de Millas C, Höer A, Häussler B. Saving money in the European healthcare systems with biosimilars. Generics and Biosimilars Initiative Journal (GaBI Journal). 2012;1(3–4):120-–126
- . Rotenstein LS, Ran N, Shivers JP, Yarchoan M, Close KL. Opportunities and challenges for biosimilars: what's on the horizon in the global insulin market? Clin Diabetes. 2012;30(4):138–150
- . Gough S. Biosimilar insulins: opportunities and challenges. Pract Diabet. 2013;30(4):146a–147a
- . Heinemann L. Biosimilar insulins. Expert Opin Biol Ther. 2012;12(8):1009–1016
- . Boven K, Stryker S, Knight J,. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int. 2005;67(6):2346–2353
- . World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs), October 2009. http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf. Accessed July 7, 2014
- . European Medicines Agency. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues. April 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/04/WC500165988.pdf. Accessed July 7, 2014
- . US Department of Health and Human Services. US Food and Drug Administration (FDA). Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Accessed July 7, 2014
- . U.S. Department of Health and Human Services. U.S. Food and Drug Administration (FDA). Guidance for Industry: Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf. Accessed July 7, 2014
- . Tam CS, Xie W, Johnson WD, Cefalu WT, Redman LM, Ravussin E. Defining insulin resistance from hyperinsulinemic-euglycemic clamps. Diabetes Care. 2012;35(7):1605–1610
- . Reddy S, Balamuralidhara V, Pramod Kumar TM, Teja CH, Reddy S. Regulatory strategies for biosimilars in regulated and emerging markets. Pharma Times. 2013;45(1):11–14. http://www.pharmatimes.com/Magazine.aspx
- . Purcell RT, Lockey RF. Immunologic responses to therapeutic biologic agents. J Investig Allergol Clin Immunol. 2008;18(5):335–342
- . World Health Organization. 56th Consultation on International Non-proprietary Names for Pharmaceutical Substances Geneva, April 2013. http://www.who.int/medicines/services/inn/56th_Executive_Summary.pdf. Accessed July 7, 2014
- . French Social Security Bill 2014. LAW No. 2013–1203 of 23 December 2013 financing of social security for 2014 (1); Part Four: Provisions Relating to Expenses for the Year 2014; Section 1: Provisions for health insurance expenditure; Article 47. http://www.legifrance.gouv.fr/affichTexteArticle.do;jsessionid=337E67BF1721F12D5DAAD1AF6C94C88B.tpdjo06v_3?idArticle=JORFARTI000028373309&cidTexte=JORFTEXT000028372809&dateTexte=29990101&categorieLien=id. Accessed July 7, 2014
- . Heinemann L, Hompesch M. Biosimilar insulins: how similar is similar? J Diabetes Sci Technol. 2011;5(3):741–754
- . Owens DR, Landgraf W, Schmidt A, Bretzel RG, Kuhlmann MK. The emergence of biosimilar insulin preparations–a cause for concern? Diabetes Technol Ther. 2012;14(11):989–996
- . Krämer I, Sauer T. The new world of biosimilars: what diabetologists need to know about biosimilar insulins. Br J Diabetes Vasc Dis. 2010;10(4):163–171
- . ClinicalTrials.gov. Comparative glucose clamp study of Wockhardt's recombinant insulin analog glargine (Glaritus) with Lantus in T1DM. http://clinicaltrial.gov/ct2/show/study/NCT01357603. Accessed July 7, 2014
- . ClinicalTrials.gov. Immunogenicity safety study of Wockhardt's recombinant insulin analogue in type 1 diabetic patients. http://clinicaltrial.gov/ct2/show/record/NCT01352663. Accessed July 7, 2014
- . Clinical Trials Registry – India. An open label, randomized, comparative trial of the safety and efficacy of Wockhardt's insulin analogue glargine (Glaritus®) with Sanofi Aventis insulin analogue Glargine (Lantus®) given along with meal time bolus of rapid acting insulin (Lispro) in type 1 diabetic patients [CTRI/2011/11/002173]. http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=3703&EncHid=&userName=glaritus. Accessed July 7, 2014
- . Biocon. Biocon announces positive results from its phase 1 comparative PK-PD study with biosimilar insulin glargine, July 2012. http://www.biocon.com/biocon_press_release_details.asp?subLink=news&Fileid=443. Accessed July 7, 2014
- . Verma M, Hazra P, Iyer H,. Basalog® is similar to Lantus® in producing glycemic control in patients with type 1 diabetes mellitus on multiple daily insulin regimens. Int J Diabetes Dev Ctries. 2011;31(1):26–31
- . Cheng SW, Lu JM, Pang CY. Studies of pharmacokinetic, pharmacodynamic properties and bioequivalence of recombinant insulin glargine injection in healthy man. Chin J Diabetes. 2010;18(8)
- . Zhu LQ, Gu QK, Zhang Y. A study on the control of fasting and postprandial hyperglycemia by glargine insulin combined with oral hypoglycemic agent. Chin J Diabetes. 2009;17(9)
- . ClinicalTrials.gov. A study to compare LY2963016 to Lantus after a single dose to subjects with type 1 diabetes mellitus. http://clinicaltrial.gov/ct2/show/NCT01600950. Accessed July 7, 2014
- . Heise T, Zhang X, Lam EC,. Duration of action of 2 insulin glargine products, LY2963016 and Lantus®, in subjects with type i diabetes mellitus (T1DM) [abstract 891–P]. Diabetes. 2014;63( suppl 1):A228
- . ClinicalTrials.gov. A study of LY2963016 in healthy participants. http://clinicaltrial.gov/ct2/show/NCT01634165. Accessed July 7, 2014
- . ClinicalTrials.gov. A study to compare LY2963016 and US-approved Lantus® after single dose administration to healthy participants. http://clinicaltrial.gov/ct2/show/NCT01688635. Accessed July 7, 2014
- . ClinicalTrials.gov. A comparison of LY2963016 to a basal insulin after a single dose in healthy subjects. http://clinicaltrial.gov/ct2/show/NCT01374178. Accessed July 7, 2014
- . ClinicalTrials.gov. A study to compare the pharmacokinetics and pharmacodynamics of LY2963016 to Lantus in healthy subjects. http://clinicaltrial.gov/ct2/show/NCT01476345. Accessed July 7, 2014
- . ClinicalTrials.gov. A study in adults with type 1 diabetes (ELEMENT 1). http://clinicaltrial.gov/ct2/show/NCT01421147. Accessed July 7, 2014
- . Blevins T, Dahl D, Rosenstock J,. Similar efficacy and safety with LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with T1DM: the ELEMENT 1 study [abstract 69-OR]. Diabetes. 2014;63( Suppl 1):A19
- . Deeg M, Ilag L, Huster WJ,. Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with T1DM or T2DM [abstract 70-OR]. Diabetes. 2014;63( Suppl 1):A19
- . ClinicalTrials.gov. A study in adults with type 2 diabetes (ELEMENT 2). http://clinicaltrial.gov/ct2/show/NCT01421459. Accessed July 7, 2014
- . Rosenstock J, Hollander P, Bhargava A,. Similar efficacy and safety with LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with T2DM: The ELEMENT 2 study [abstract 64-OR]. Diabetes. 2014;63( Suppl 1):A17
- . ClinicalTrials.gov. A study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MK-1293 compared with a basal insulin in participants with type 1 diabetes (MK-1293–005). http://clinicaltrials.gov/show/NCT02059174. Accessed July 7, 2014
- . ClinicalTrials.gov. A study of the safety and efficacy of MK-1293 compared to LantusTM in participants with type 1 diabetes mellitus (T1DM) (MK-1293–003). http://clinicaltrials.gov/show/NCT02059161. Accessed July 7, 2014
- . ClinicalTrials.gov. The safety and efficacy of MK-1293 versus LantusTM in participants with type 2 diabetes mellitus (MK-1293–006). http://clinicaltrials.gov/show/NCT02059187. Accessed July 7, 2014
- . ClinicalTrials.gov. Comparative glucose clamp study of Wockhardt's human isophane insulin with Novolin N, in healthy subjects. http://clinicaltrials.gov/show/NCT00772265. Accessed July 7, 2014
- . ClinicalTrials.gov. Comparative glucose clamp study of Wockhardt's insulin human regular for injection and Actrapid, in type 1 diabetics. http://clinicaltrials.gov/show/NCT00752180. Accessed July 7, 2014
- . ClinicalTrials.gov. Comparative glucose clamp study of Wockhardt's insulin human regular for injection and Actrapid, in healthy subjects. http://clinicaltrials.gov/show/NCT00719108. Accessed July 7, 2014
- . ClinicalTrials.gov. Comparative glucose clamp study of Wockhardt's insulin human regular for injection and Novolin R, in healthy subjects. http://clinicaltrials.gov/show/NCT00596063. Accessed July 7, 2014
- . ClinicalTrials.gov. Immunosafety study of recombinant human insulins in type 1 diabetics. http://clinicaltrials.gov/ct2/show/NCT01308437. Accessed July 7, 2014
- . Segal D, Tupy D, Distiller L. The Biosulin equivalence in standard therapy (BEST) study – a multicentre, open-label, non-randomised, interventional, observational study in subjects using Biosulin 30/70 for the treatment of insulin-dependent type 1 and type 2 diabetes mellitus. S Afr Med J. 2013;103(7):458–460
- . Wockhardt. Search Products. http://www.wockhardt.com/products/search-products.aspx. Accessed July 7, 2014
- . Friedrichs A, Bohnet J, Korger V, Adler S, Schubert-Zsilavecz M, Abdel-Tawab M. Dose accuracy and injection force of different insulin glargine pens. J Diabetes Sci Technol. 2013;7(5):1346–1353
- . Biocon. Biocon enhances partnership with Mylan through strategic collaboration for insulin products…, February 2013. http://www.biocon.com/biocon_press_release_details.asp?subLink=news&Fileid=467. Accessed July 7, 2014
- . Landgraf W, Schmidt A, Schäfer E, Schmeier E, Jochum M. Insulin glargine by-product profiles: a fingerprint of the biotechnological production process. http://www.codhy.com/LA/2012/Uploads/assets/poster%20board%2028.pdf. Accessed July 7, 2014
- . European Medicines Agency. Summary of opinion (initial authorisation). Abasria (insulin glargine), June 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_–_Initial_authorisation/human/002835/WC500169353.pdf. Accessed July 7, 2014
- . Lilly. Eli Lilly and Company and Boehringer Ingelheim announce new drug application filing in the U.S. for new insulin glargine product, December 2013. https://investor.lilly.com/releasedetail.cfm?releaseid=815459. Accessed July 7, 2014
- . Zhang X, Lam EC, Seger ME,. Comparative pharmacokinetics and pharmacodynamics of two insulin glargine products, LY2963016 and Lantus®, in healthy subjects at two dose levels [abtract 890-P]. Diabetes. 2014;63( suppl 1):A227
- . Linnebjerg H, Lam EC, Seger ME,. Comparative pharmacokinetics (PK) and pharmacodynamics (PD) of LY2963016 insulin glargine and EU- and U.S.-approved versions of Lantus® insulin glargine in healthy subjects [abstract 889-P]. Diabetes. 2014;63( suppl 1):A227
- . van der Burg T. Injection force of SoloSTAR® compared with other disposable insulin pen devices at constant volume flow rates. J Diabetes Sci Technol. 2011;5(1):150–155
- . Aronson R, Gibney MA, Oza K, Bérubé J, Kassler-Taub K, Hirsch L. Insulin pen needles: effects of extra-thin wall needle technology on preference, confidence, and other patient ratings. Clin Ther. 2013;35(7):923–933
- . Samsung Bioepis. Samsung Bioepis and Merck enter worldwide collaboration agreement to develop and commercialize biosimilar insulin glargine candidate for diabetes, February 2014. http://www.samsung-bioepis.com/newsroom1/newsroom_1.html. Accessed July 7, 2014
- . Johnson IS. Human insulin from recombinant DNA technology. Science. 1983;219(4585):632–637
- . Biocon. Biocon announces positive results from its global phase 3 study with recombinant human insulin, October 2012. http://www.biocon.com/biocon_press_release_details.asp?subLink=news&Fileid=457. Accessed July 7, 2014
- . European Medicines Agency. Withdrawal Assessment Report for Insulin Human Rapid Marvel, February 2008. http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500067086.pdf. Accessed July 7, 2014
- . European Medicines Agency. Withdrawal Assessment Report for Insulin Human Long Marvel, February 2008. http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500067170.pdf. Accessed July 7, 2014
- . European Medicines Agency. Withdrawal Assessment Report for Insulin Human 30/70 Mix Marvel, February 2008. http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500067169.pdf. Accessed July 7, 2014
- . Kuhlmann M, Marre M. Lessons learned from biosimilar epoetins and insulins. Br J Diabetes Vasc Dis. 2010;10(2):90–97
- . Sanofi. IR Thematic Call on Diabetes. San Francisco – June 16th, 2014. http://en.sanofi.com/Images/36711_IRCall_2014_ADA_FINAL.pdf. Accessed July 7, 2014
- . Kannan V, Narayanaswamy P, Gadamsetty D, Hazra P, Khedkar A, Iyer H. A tandem mass spectrometric approach to the identification of O-glycosylated glargine glycoforms in active pharmaceutical ingredient expressed in Pichia pastoris. Rapid Commun Mass Spectrom. 2009;23(7):1035–1042
- . Lee JF, Litten JB, Grampp G. Comparability and biosimilarity: considerations for the healthcare provider. Curr Med Res Opin. 2012;28(6):1053–1058
- . Miletich J, Eich G, Grampp G, Mounho B. Biosimilars 2.0: guiding principles for a global “patients first” standard. MAbs. 2011;3(3):318–325